Oxford team behind coronavirus jab take big step towards producing cheap and effective vaccine for malaria at stage-three trials

 The same Oxford team behind a successful coronavirus vaccine are on the verge of entering the final stage of human trials in their jab against malaria. 

The Jenner Institute director Adrian Hill said the malaria vaccine will be tested on 4,800 children in Africa next year after early trials yielded promising results.

The Jenner Institute director Adrian Hill (pictured) said the malaria vaccine will be tested on 4,800 children in Africa next year

The Jenner Institute director Adrian Hill (pictured) said the malaria vaccine will be tested on 4,800 children in Africa next year

Professor Hill said he hoped the jab could eventually combat the almost half a million annual deaths from the disease, during an interview with The Times. 

He said: 'Malaria is a public health emergency.

'A lot more people will die in Africa this year from malaria than will die from Covid. I don't mean twice as many - probably ten times.'

He added that the vaccine is going to be 'available in very large amounts' and is going to 'be very low priced'.   

Professor Hill said the vaccine could be in use by 2024, should the final human trials in Burkina Faso, Kenya, Tanzania and Mali be successful next year. 

The Oxford/AstraZeneca coronavirus vaccine is currently awaiting regulatory approval for use in the UK.         

The institute's coronavirus and malaria vaccines are intended to be cheap and available at scale in developing countries. 

Despite more than a century of research, no vaccine is fully licensed for malaria, according to The Times.  

Early phase-two trials have proved to be promising for the disease, which has been hard to tackle in part because it is a parasite, which is bigger than a virus.



They have partnered with the Serum Institute in India, which said it could make between 200 million and 300 million doses a year.    

The Jenner Institute has been backed by the government, the EU, the Wellcome Trust and the Gates Foundation. 

The Tory MP Andrew Mitchell, said he was concerned that without continued government funding Britain would not be involved in any distribution of the jab.

He said: 'This is such exciting news — malaria kills a child every two seconds in the poorest parts of the world.

The Oxford/AstraZeneca coronavirus vaccine is currently awaiting regulatory approval for use in the UK (file image)

The Oxford/AstraZeneca coronavirus vaccine is currently awaiting regulatory approval for use in the UK (file image)

How does the Oxford vaccine differ to Pfizer's?
Loaded: 0%
Progress: 0%
0:00
Previous
Play
Skip
Mute
Current Time0:00
/
Duration Time2:24
Fullscreen
Need Text

'It would be a tragedy if cuts to the aid budget mean the UK fails to get the credit for delivering the full benefits of this amazing science.' 

In a trial on young adult UK volunteers who were deliberately infected with malaria, it was more than 80 per cent effective. 

The UK has secured 40million doses of the Pfizer/BioNTech vaccine, with 10million due in the UK by the end of the year. Matt Hancock revealed 800,000 doses will be available next week. 

Oxford team behind coronavirus jab take big step towards producing cheap and effective vaccine for malaria at stage-three trials Oxford team behind coronavirus jab take big step towards producing cheap and effective vaccine for malaria at stage-three trials Reviewed by Your Destination on December 06, 2020 Rating: 5

No comments

TOP-LEFT ADS